Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Biochem Biophys Res Commun ; 725: 150254, 2024 Sep 17.
Artigo em Inglês | MEDLINE | ID: mdl-38901223

RESUMO

Decreased pancreatic ß-cell volume is a serious problem in patients with type 2 diabetes mellitus, and there is a need to establish appropriate treatments. Increasingly, sodium/glucose cotransporter 2 (SGLT2) inhibitors, which have a protective effect on pancreatic ß-cells, are being prescribed to treat diabetes; however, the underlying mechanism is not well understood. We previously administered SGLT2 inhibitor dapagliflozin to a mouse model of type 2 diabetes and found significant changes in gene expression in the early-treated group, which led us to hypothesize that epigenetic regulation was a possible mechanism of these changes. Therefore, we performed comprehensive DNA methylation analysis by methylated DNA immunoprecipitation using isolated pancreatic islets after dapagliflozin administration to diabetic model mice. As a result, we identified 31 genes with changes in expression due to DNA methylation changes. Upon immunostaining, cystic fibrosis transmembrane conductance regulator and cadherin 24 were found to be upregulated in islets in the dapagliflozin-treated group. These molecules may contribute to the maintenance of islet morphology and insulin secretory capacity, suggesting that SGLT2 inhibitors' protective effect on pancreatic ß-cells is accompanied by DNA methylation changes, and that the effect is long-term and not temporary. In future diabetes care, SGLT2 inhibitors may be expected to have positive therapeutic effects, including pancreatic ß-cell protection.


Assuntos
Compostos Benzidrílicos , Metilação de DNA , Diabetes Mellitus Tipo 2 , Glucosídeos , Ilhotas Pancreáticas , Inibidores do Transportador 2 de Sódio-Glicose , Animais , Compostos Benzidrílicos/farmacologia , Compostos Benzidrílicos/uso terapêutico , Metilação de DNA/efeitos dos fármacos , Glucosídeos/farmacologia , Glucosídeos/uso terapêutico , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/genética , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Mellitus Tipo 2/patologia , Camundongos , Ilhotas Pancreáticas/metabolismo , Ilhotas Pancreáticas/efeitos dos fármacos , Ilhotas Pancreáticas/patologia , Masculino , Inibidores do Transportador 2 de Sódio-Glicose/farmacologia , Camundongos Endogâmicos C57BL , Modelos Animais de Doenças , Diabetes Mellitus Experimental/genética , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/tratamento farmacológico , Diabetes Mellitus Experimental/patologia , Epigênese Genética/efeitos dos fármacos , Regulação da Expressão Gênica/efeitos dos fármacos , Caderinas/metabolismo , Caderinas/genética
2.
Kobe J Med Sci ; 69(1): E1-E8, 2023 Mar 02.
Artigo em Inglês | MEDLINE | ID: mdl-37088693

RESUMO

The incidence of type 2 diabetes is reported to be lower in frequent coffee drinkers than in non-coffee drinkers. To elucidate the mechanism by which coffee prevents the onset of type 2 diabetes, we analyzed how caffeine and chlorogenic acid, which are components of coffee, alter insulin signaling in MIN6 cells, a mouse pancreatic Β cell line. The results showed that caffeine improved insulin signaling under endoplasmic reticulum stress, and chlorogenic acid protected pancreatic Β cells by enhancing the expression of insulin receptor substrate 2 via cAMP response element-binding protein and promoting insulin signaling downstream of insulin receptor substrate 2. In addition, chlorogenic acid was a potent antioxidant for the protection of pancreatic Β cells. Furthermore, in vivo and in vitro analyses revealed that the pancreatic Β cell-protective effect of chlorogenic acid was mediated by the alleviation of endoplasmic reticulum stress. The results suggest that these components of coffee have the potential to reduce the pathogenesis of type 2 diabetes and improve pancreatic Β cell insufficiency.


Assuntos
Diabetes Mellitus Tipo 2 , Células Secretoras de Insulina , Animais , Camundongos , Cafeína/farmacologia , Insulina/metabolismo , Ácido Clorogênico/farmacologia , Células Secretoras de Insulina/metabolismo , Proteínas Substratos do Receptor de Insulina/metabolismo , Diabetes Mellitus Tipo 2/prevenção & controle
3.
Biochem Biophys Res Commun ; 652: 121-130, 2023 04 16.
Artigo em Inglês | MEDLINE | ID: mdl-36842323

RESUMO

Eif2ak4, a susceptibility gene for type 2 diabetes, encodes GCN2, a molecule activated by amino acid deficiency. Mutations or deletions in GCN2 in pancreatic ß-cells increase mTORC1 activity by decreasing Sestrin2 expression in a TSC2-independent manner. In this study, we searched for molecules downstream of GCN2 that suppress mTORC1 activity in a TSC2-dependent manner. To do so, we used a pull-down assay to identify molecules that competitively inhibit the binding of the T1462 phosphorylation site of TSC2 to 14-3-3. l-asparaginase was identified. Although l-asparaginase is frequently used as an anticancer drug for acute lymphoblastic leukemia, little is known about endogenous l-asparaginase. l-Asparaginase, which is expressed downstream of GCN2, was found to bind 14-3-3 and thereby to inhibit its binding to the T1462 phosphorylation site of TSC2 and contribute to TSC2 activation and mTORC1 inactivation upon TSC2 dephosphorylation. Further investigation of the regulation of mTORC1 activity in pancreatic ß-cells by l-asparaginase should help to elucidate the mechanism of diabetes and insulin secretion failure during anticancer drug use.


Assuntos
Antineoplásicos , Diabetes Mellitus Tipo 2 , Células Secretoras de Insulina , Humanos , Alvo Mecanístico do Complexo 1 de Rapamicina/metabolismo , Asparaginase , Células Secretoras de Insulina/metabolismo , Proteínas Serina-Treonina Quinases/metabolismo
5.
Br J Haematol ; 144(5): 742-54, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19055667

RESUMO

Upshaw-Schulman syndrome (USS) is a congenital thrombotic thrombocytopenic purpura (TTP) due to mutations in the gene that encodes for ADAMTS13 (ADAMTS13), but its clinical signs may be mild or absent during childhood. We have identified 37 patients with USS (24 females, 13 males) belonging to 32 families. The nine women from six families who were diagnosed during their first pregnancy are the focus of this report. Six of the nine women had episodes of thrombocytopenia during childhood misdiagnosed as idiopathic thrombocytopenic purpura. Thrombocytopenia occurred during the second-third trimesters in each of their 15 pregnancies, with 16 babies (one twin pregnancy), often followed by TTP. Of 15 pregnancies, eight babies were stillborn or died soon after birth, and the remaining seven were all premature except one, who was born naturally following plasma infusions to the mother that had started at 8 weeks' gestation. All nine USS women had severely deficient ADAMTS13 activity. ADAMTS13 analyses demonstrated that eight women were compound heterozygotes of Y304C/G525D (2 siblings), R125VfsX6/Q1302X (2 siblings), R193W/R349C (2 siblings), I178T/Q929X, and R193W/A606P; one woman was homozygous for R193W. Only the R193W mutation has been previously reported. These observations emphasize the importance of measuring ADAMTS13 activity in the evaluation of thrombocytopenia during childhood and pregnancy.


Assuntos
Complicações Hematológicas na Gravidez/genética , Púrpura Trombocitopênica Trombótica/congênito , Púrpura Trombocitopênica Trombótica/genética , Proteínas ADAM/antagonistas & inibidores , Proteínas ADAM/sangue , Proteínas ADAM/genética , Proteína ADAMTS13 , Adulto , Western Blotting , Análise Mutacional de DNA , Feminino , Morte Fetal , Predisposição Genética para Doença , Genótipo , Heterozigoto , Humanos , Recém-Nascido , Masculino , Mutação , Linhagem , Gravidez , Complicações Hematológicas na Gravidez/mortalidade , Segundo Trimestre da Gravidez , Terceiro Trimestre da Gravidez , Púrpura Trombocitopênica Trombótica/mortalidade , Risco
6.
Clin Nucl Med ; 28(9): 766-8, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12973003

RESUMO

Remitting seronegative symmetric synovitis with pitting edema (RS3PE) was first reported by McCarty et al in 1985 and refers to a rheumatologic set of symptoms with acute onset, with no erosive bone lesions, with seronegative findings, affecting the elderly more frequently, and showing an excellent prognosis with low-dose steroid therapy. Although these characteristics make it possible to differentiate it from rheumatoid arthritis and rheumatic polymyalgia, there have been very few reports on the imaging findings. The authors present scintigraphic and magnetic resonance images in a case of RS3PE.


Assuntos
Osso e Ossos/diagnóstico por imagem , Imageamento por Ressonância Magnética , Sinovite/diagnóstico por imagem , Medronato de Tecnécio Tc 99m/análogos & derivados , Edema/diagnóstico , Edema/diagnóstico por imagem , Feminino , Radioisótopos de Gálio , Humanos , Pessoa de Meia-Idade , Cintilografia , Compostos Radiofarmacêuticos , Sinovite/diagnóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA